Risperidone vs Aripiprazole

How they're similar

Risperidone and aripiprazole share a lot at the class level and in how they're used in practice.

• Both are second-generation atypical antipsychotics.
• Both are FDA-approved for schizophrenia and for bipolar mania. Both are also approved for autism-related irritability in children and adolescents, which is a relatively rare indication in psychiatric prescribing.
• Both carry the class boxed warning about increased mortality in elderly patients with dementia-related psychosis.
• Both come in oral tablets and both have long-acting injectable forms. Risperidone has several LAI options (Risperdal Consta, Perseris, Uzedy), and aripiprazole has Abilify Maintena and Aristada.
• Both can cause sedation, though generally less than olanzapine or quetiapine.
• Both require baseline and follow-up metabolic monitoring, though the metabolic burden is much smaller with aripiprazole than with risperidone.
• Both are available as inexpensive generics.

The overlap at the indication level means these two drugs often show up in the same clinical decision. When a prescriber is picking between antipsychotics for schizophrenia or bipolar mania, especially for a first episode or a first switch, risperidone and aripiprazole are frequently on the same short list. What tips the choice is usually the side effect profile.

How they differ

The differences are meaningful and show up quickly in how patients feel on each drug. Risperidone hits dopamine harder and comes with the effects that follow from that. Aripiprazole's partial agonism gives it a different pattern.

The mechanism difference is where all the practical differences come from. Risperidone is a straightforward D2 antagonist, meaning it blocks dopamine at those receptors. That's the classic antipsychotic action. At usual doses it works well, but as the dose climbs above about 4 mg a day, side effects that come from strong D2 blockade become more common: extrapyramidal symptoms (EPS), which include stiffness, tremor, slowed movement, and restlessness, along with prolactin elevation.

Aripiprazole works differently. It's a partial agonist at D2, which means it acts partly like dopamine itself at the receptor rather than blocking it entirely. In areas of the brain where dopamine is too high (as in psychosis), aripiprazole's partial agonism functions closer to blockade and reduces dopamine signaling. In areas where dopamine is low, aripiprazole provides some activity of its own. That mechanism explains most of aripiprazole's distinctive profile. It causes less prolactin elevation because it doesn't fully block D2. It causes less EPS at usual doses because it doesn't produce complete dopamine blockade. It causes less weight gain because it doesn't hit the receptors that drive that effect in the same way.

Where aripiprazole stands out unfavorably is akathisia. Akathisia is a specific kind of restlessness that patients describe as an inability to sit still, an internal jitteriness, or a driven feeling. It can be distressing enough to lead people to stop the medication. Aripiprazole causes akathisia at a higher rate than most other antipsychotics, and it's often the main tolerability issue when it comes up. Some patients experience it early in treatment and it fades. For others it persists. It can be treated with dose reduction, propranolol, benzodiazepines, or a switch.

Weight and metabolic burden differ significantly. Risperidone causes moderate weight gain and can raise blood sugar and lipids. Aripiprazole is generally weight-neutral in the short term and has much less impact on glucose and lipids. Over years of use, some weight gain still occurs on aripiprazole for some patients, but it's usually less than with most other atypicals. For a patient who's already overweight, prediabetic, or who has a family history of diabetes, this is often a decisive difference.

Prolactin runs opposite. Risperidone raises prolactin more than any other antipsychotic in current use, sometimes into ranges you'd see with a pituitary tumor. That can cause breast enlargement in men, milk production not related to pregnancy, missed periods, lowered sex drive, and erectile problems, along with long-term concerns about bone density. Aripiprazole doesn't raise prolactin. In fact, it can lower it, and aripiprazole is sometimes added to another antipsychotic specifically to bring prolactin levels back down when hyperprolactinemia is a problem.

Sedation and activation also differ. Risperidone is somewhat sedating, though less than olanzapine or quetiapine. Aripiprazole is less sedating and can sometimes feel activating, meaning it can worsen anxiety, cause insomnia, or make some patients feel wired especially in the first weeks. This is another difference that shapes the choice: a patient with severe insomnia and agitation might do better on the more sedating drug, and a patient who values energy and alertness might do better on aripiprazole.

Aripiprazole has an approval that risperidone doesn't share: it's FDA-approved as an adjunct for major depressive disorder when a first antidepressant hasn't been enough. That approval, along with the evidence behind it, makes aripiprazole a common add-on in treatment-resistant depression. Risperidone can be used off-label for that purpose but doesn't carry the formal approval.

Both drugs are approved for autism-related irritability in children and adolescents. Both have LAI forms, and both are widely used in that role.

Side effect tendencies

The side effects patients notice most are different for these two drugs.

On risperidone, the effects that tend to come to the front are sedation, weight gain, prolactin-related symptoms, and, at higher doses, movement effects. Sedation is often noticeable in the first week or two. Weight gain builds over the first months. Prolactin symptoms can take weeks to appear but often persist. Movement effects are dose-related, and above about 4 mg a day the risk goes up. Older patients are more susceptible to all of these, and slower titration is standard.

On aripiprazole, the effect that tends to come to the front is akathisia. Patients often describe restlessness, an inability to sit still, or a driven feeling that appears within the first days or weeks. Anxiety and insomnia can also be problems early on. Weight gain is usually minimal at first, and metabolic labs generally hold steady. Sedation is uncommon. Sexual side effects are less common than with risperidone.

Both drugs can cause the same set of general antipsychotic effects: dry mouth, constipation, dizziness, and rare but serious complications like neuroleptic malignant syndrome and tardive dyskinesia. Tardive dyskinesia is a risk with any antipsychotic over years of use, and while both aripiprazole and risperidone are considered lower-risk than older antipsychotics, neither is free of it.

Both drugs can cause impulse control problems, a side effect that's been more strongly associated with aripiprazole. This includes pathological gambling, hypersexuality, compulsive shopping, and binge eating. These effects are relatively uncommon but real, and the FDA added a specific warning about them to aripiprazole's label. Patients starting aripiprazole should be counseled about this.

What tips the choice

Because both drugs work well for schizophrenia and bipolar mania at usual doses, the choice usually comes down to which side effect profile fits the patient best.

A clinician might choose risperidone when the patient can tolerate some sedation, when metabolic risk factors are limited, and when the patient hasn't had prolactin problems on other antipsychotics. It's a common choice in early psychosis, in outpatient bipolar treatment, and in autism-related irritability. Prior response weighs in. A patient who's done well on risperidone before usually returns to it.

A clinician might choose aripiprazole when metabolic burden is a real concern, when a patient can't afford to gain weight or develop blood sugar problems, or when prolactin elevation has been a problem on other drugs. Aripiprazole is often the first choice for young patients who need long-term antipsychotic treatment and who would be significantly harmed by 10 to 20 pounds of weight gain a year. It's also the drug most often chosen when a patient is being treated for major depressive disorder that hasn't responded fully to an antidepressant, because of that specific FDA approval.

Akathisia risk is the main reason to avoid aripiprazole. A patient who's already anxious, who has a history of severe akathisia on another antipsychotic, or who's especially sensitive to activating effects may not do well on aripiprazole. A patient with insomnia as a prominent complaint may find aripiprazole makes it worse.

Long-acting injectables factor in when adherence is a concern. Both drugs have well-established LAI options, so if that's part of the treatment plan, either drug can support it.

Prior response and family response matter, as with any psychiatric drug. If a person or a close family member has had a specific good or bad experience with either drug, that shapes the decision.

Common questions

What is akathisia and why does aripiprazole cause it more? Akathisia is a specific kind of inner restlessness that patients describe as an inability to sit still, an internal jitteriness, or a compulsion to keep moving. It's not the same as anxiety, though the two can feel similar. It's a movement side effect that comes from dopamine changes in specific brain circuits. Aripiprazole's partial agonism at D2 receptors, especially at lower doses where it hits D2 without fully agonizing them, seems to drive the effect. Not every patient on aripiprazole gets akathisia, and when it happens it can often be managed with dose reduction, propranolol, or a switch. It's the most common reason patients stop aripiprazole.

Why is aripiprazole considered better for weight? Aripiprazole doesn't hit the receptors that drive weight gain as hard as most other atypicals. Its partial agonism at D2 and its different pattern of binding to histamine and other receptors means less appetite stimulation and less metabolic disruption. Head-to-head studies consistently show less weight gain on aripiprazole than on olanzapine, risperidone, or quetiapine. That doesn't mean nobody gains weight on it, but for most patients the weight effect is small.

Can I use aripiprazole for depression that isn't bipolar? Yes. Aripiprazole has an FDA approval as an adjunct for major depressive disorder, meaning it's added to an antidepressant when that antidepressant hasn't been enough. It's usually used at lower doses in this setting, often 2 to 15 mg a day, compared to the higher doses used for schizophrenia. It's one of the most common augmentation strategies for treatment-resistant depression.

Which is more likely to cause sexual side effects? Risperidone is more likely to cause sexual side effects, largely because of its prolactin elevation. Lowered sex drive, erectile problems, and delayed orgasm are common on risperidone. Aripiprazole has less of these effects, and in fact aripiprazole is sometimes added to another antipsychotic specifically to reduce prolactin and the sexual side effects that come with it. This is one of the specific advantages aripiprazole has for patients who value sexual functioning.

Do I need labs while on either of these? Yes, though the monitoring is less intensive than with drugs like olanzapine or clozapine. Standard metabolic monitoring applies to both: weight and blood pressure at visits, fasting glucose and lipids at baseline, at three months, and then at least annually. On risperidone, some clinicians also check prolactin if symptoms come up. Aripiprazole's lower metabolic burden doesn't remove the need for monitoring, but the values tend to hold steadier over time.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Risperidone (Risperdal) prescribing information.
2. U.S. Food and Drug Administration. Aripiprazole (Abilify) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute of Mental Health. Mental health medications.